Q2 2018 13F Holders as of 6/30/2018
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
132M
-
Number of holders
-
300
-
Total 13F shares, excl. options
-
91.5M
-
Shares change
-
+655K
-
Total reported value, excl. options
-
$9.01B
-
Value change
-
+$41.3M
-
Put/Call ratio
-
0.53
-
Number of buys
-
172
-
Number of sells
-
-111
-
Price
-
$98.49
Significant Holders of ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) as of Q2 2018
376 filings reported holding ALNY - ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK as of Q2 2018.
ALNYLAM PHARMACEUTICALS, INC. - COMMON STOCK (ALNY) has 300 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 91.5M shares
of 132M outstanding shares and own 69.58% of the company stock.
Largest 10 shareholders include FMR LLC (15.1M shares), WELLINGTON MANAGEMENT GROUP LLP (11.8M shares), VANGUARD GROUP INC (7.54M shares), BlackRock Inc. (6.14M shares), PRICE T ROWE ASSOCIATES INC /MD/ (5.21M shares), DODGE & COX (4.65M shares), BAILLIE GIFFORD & CO (4.23M shares), STATE STREET CORP (2.25M shares), PERCEPTIVE ADVISORS LLC (1.85M shares), and UBS ASSET MANAGEMENT AMERICAS INC (1.36M shares).
This table shows the top 300 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.